Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
- Conditions
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 124
- Registration Number
- NCT02357147
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
- Conditions
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 27
- Registration Number
- NCT01761240
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisChildhood Burkitt Lymphoma
- Interventions
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 27
- Registration Number
- NCT01748721
- Locations
- ๐บ๐ธ
Washington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธChildren's Hospital of Alabama, Birmingham, Alabama, United States
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
- Conditions
- Interventions
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 209
- Registration Number
- NCT01574716
- Locations
- ๐บ๐ธ
Sarcoma Oncology Center, Santa Monica, California, United States
๐บ๐ธSidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 6
- Registration Number
- NCT01521325
- Locations
- ๐บ๐ธ
National Cacner Institue, Bethesda, Maryland, United States
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
- Conditions
- Interventions
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 154
- Registration Number
- NCT01507545
- Locations
- ๐บ๐ธ
Providence St. Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States
๐บ๐ธSt. Jude Heritage Healthcare, Fullerton, California, United States
๐บ๐ธComprehensive Blood and Cancer Center, Bakersfield, California, United States
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 20
- Registration Number
- NCT01357759
- Locations
- ๐บ๐ธ
Axis Clinical Trials, Los Angeles, California, United States
๐บ๐ธSeaview Jacksonville, LLC, Jacksonville, Florida, United States
๐บ๐ธLynn Health Science Institute, Oklahoma City, Oklahoma, United States
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
- Conditions
- Interventions
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 130
- Registration Number
- NCT01218516
- Locations
- ๐บ๐ธ
Clinical Trials and Research Associates, Inc., Montebello, California, United States
๐บ๐ธMedical Specialists of the Palm Beaches, Deerfield Beach, Florida, United States
๐บ๐ธUniversity of Chicago Medical Center, Chicago, Illinois, United States
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 18
- Registration Number
- NCT01212276
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
- Conditions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Morphotek
- Registration Number
- NCT01203618
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States